Free Trial
ASX:BOD

Bod Science (BOD) Stock Price, News & Analysis

About Bod Science Stock (ASX:BOD)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$4.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through four segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, OTC Herbals, and Corporate. It engages in the development of cannabidiol and hemp products for consumers; and development and distribution of therapeutics medicinal cannabis products for medical markets. The company provides Flexofytol, an anti-inflammatory derived from a scientifically validated and clinically trialed turmeric extract that helps in improving joint pain and stiffness, joint health, limiting the ageing of cartilage, and reducing inflammation caused by mild arthritis; and Sedistress, a passion flower extract that reduces the symptoms of stress, anxiety, and insomnia, as well as contract manufacturing services. The company was formerly known as Bod Australia Limited and changed its name to Bod Science Limited in December 2022. Bod Science Limited was incorporated in 2014 and is based in Double Bay, Australia.

Receive BOD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bod Science and its competitors with MarketBeat's FREE daily newsletter.

BOD Stock News Headlines

URGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?
According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the highest levels. But I believe a little-known coin could benefit even more—and I’ve revealed its name and ticker in a new briefing.
See More Headlines

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
ASX:BOD
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,950,000.00
Net Margins
-352.17%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.32 million
Price / Cash Flow
N/A
Book Value
A($0.03) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$4.26 million
Optionable
Not Optionable
Beta
1.46
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (ASX:BOD) was last updated on 5/14/2025 by MarketBeat.com Staff
From Our Partners